AKT1 and Familial gastric cancer: When applying the most stringent criteria for drug activity by combining both criteria high quality drug response curve (drugs yielding high quality CRCs including −1.1, −1.2, −2.1, and −2.2) and potency (Δ-log[AC50] (SB.mhdgc-1–SB.msgc-1) < 1) and comparing drug activity profiles between c.1380delA CDH1 SB.mhdgc-1 and SB.msgc-1 cells, compounds targeting mTOR, PI3KCA, and AKT1 were significantly (p value < 0.01) enriched as selectively active in hereditary diffuse gastric cancer versus sporadic SB.msgc-1 cells (Additional file 8: Figure S6A).